These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 18802209)
1. Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Covic A; Cannata-Andia J; Cancarini G; Coppo R; Frazão JM; Goldsmith D; Ronco P; Spasovski GB; Stenvinkel P; Utas C; Wiecek A; Zoccali C; London G Nephrol Dial Transplant; 2008 Dec; 23(12):3731-7. PubMed ID: 18802209 [No Abstract] [Full Text] [Related]
2. Biosimilars and biopharmaceuticals: what the nephrologist needs to know--a position paper by the ERA-EDTA Council. Shaldon S Nephrol Dial Transplant; 2009 May; 24(5):1700-1; discussion 1701. PubMed ID: 19329532 [No Abstract] [Full Text] [Related]
3. In-process testing and limits. Sjöholm I Dev Biol Stand; 1997; 91():73-8. PubMed ID: 9413685 [No Abstract] [Full Text] [Related]
4. The role of the ERA-EDTA in organizing continuing medical education in Europe for nephrology, dialysis and renal transplantation. Coppo R J Nephrol; 2006; 19(2):126-30. PubMed ID: 16736408 [TBL] [Abstract][Full Text] [Related]
5. The role of assay validation in specification development. Baffi RA Dev Biol Stand; 1997; 91():105-13. PubMed ID: 9413687 [TBL] [Abstract][Full Text] [Related]
6. Development of specifications for biotechnology products--perspective from Europe. Trouvin JH Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679 [No Abstract] [Full Text] [Related]
11. Global vision about the biological medicinal products: biosimilars (April, 2009). Zuñiga L; Calvo B Curr Pharm Biotechnol; 2009 Dec; 10(8):772-4. PubMed ID: 19939216 [TBL] [Abstract][Full Text] [Related]
12. [Position statements regarding usage of biosimilars of Epoetins. Position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique]. Bouchet JL; Brunet P; Canaud B; Chanliau J; Combe C; Deray G; Houillier P; Kourilsky O; Ledneva E; Niaudet P; Ortiz JP; Pavlovic M; Ryckelynck JP; Singlas E; Verhelst D; ; ; Nephrol Ther; 2009 Feb; 5(1):61-6. PubMed ID: 19084489 [TBL] [Abstract][Full Text] [Related]
13. [Overregulation and unnecessary animal testing: requirements for market approval of biopharmaceuticals too rigid]. Schellekens H Ned Tijdschr Geneeskd; 2012; 156(50):A5723. PubMed ID: 23231875 [TBL] [Abstract][Full Text] [Related]
14. Biopharmaceuticals -- discovery, development and manufacturing. Jungbauer A; Graumann K Biotechnol J; 2012 Dec; 7(12):1422-3. PubMed ID: 23213011 [TBL] [Abstract][Full Text] [Related]
15. Thirty years of preclinical safety evaluation of biopharmaceuticals: Did scientific progress lead to appropriate regulatory guidance? Kooijman M; van Meer PJ; Moors EH; Schellekens H Expert Opin Drug Saf; 2012 Sep; 11(5):797-801. PubMed ID: 22861668 [TBL] [Abstract][Full Text] [Related]
16. Industry views of biosimilar development in Japan. Horikawa H; Tsubouchi M; Kawakami K Health Policy; 2009 Jul; 91(2):189-94. PubMed ID: 19157628 [TBL] [Abstract][Full Text] [Related]
18. Somatonorm (somatrem) and Genotropin (somatropin): two case studies. Fryklund L Biologicals; 2006 Mar; 34(1):69-70. PubMed ID: 16330223 [No Abstract] [Full Text] [Related]
19. Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals. Tovey MG; Lallemand C Bioanalysis; 2012 Sep; 4(17):2179-90. PubMed ID: 23013400 [TBL] [Abstract][Full Text] [Related]
20. Current legal, regulatory, and scientific implications of biosimilars. Introduction. Wenzel RG Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S1. PubMed ID: 18591710 [No Abstract] [Full Text] [Related] [Next] [New Search]